Form 4: Twist Bioscience CFO Sells Shares Under 10b5-1 Plan

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, has sold 4,000 shares of common stock as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corporation, reported a transaction on April 17, 2026.
• The transaction involved the sale of 4,000 shares of common stock.
• This sale was executed under a Rule 10b5-1 trading plan, adopted on May 8, 2025, which is designed to comply with affirmative defense conditions for Rule 10b5-1(c).
• Following the transaction, Laponis beneficially owns 118,694 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock sale by an executive under a pre-arranged plan, which is a common and expected event for publicly traded companies.

Negatives

• The Chief Financial Officer sold a portion of their holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed by executives to diversify holdings or manage personal finances without triggering insider trading concerns.

Stakeholder Impact

• Shareholders: The sale by a key executive may be monitored, but the use of a 10b5-1 plan mitigates concerns about insider trading, suggesting a planned divestment rather than a reaction to negative company news.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Sale, Twist Bioscience, Adam Laponis, Chief Financial Officer, Beneficial Ownership